Department of Oncology, CHUV, Lausanne, 1011, Switzerland.
Department of Radiology and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.
Cardiovasc Intervent Radiol. 2019 Sep;42(9):1221-1229. doi: 10.1007/s00270-018-2074-1. Epub 2018 Sep 12.
The therapeutic options in the treatment of cancer therapy have been recently significantly increased with systemic immune-targeted therapies. Novel immunotherapy approaches based on immune checkpoint blockade or engineered cytotoxic T lymphocytes have reached late-stage clinical development, with highly encouraging results. The success of cancer immunotherapy has generated a tremendous interest in further developing and exploring these strategies in combination with other approaches such as radiotherapy and local ablative therapies in oncology. The goal of this review is to discuss current approaches in immunotherapy and provide simple and constructive explanations on their mechanisms of action as well as certain more common and serious toxicities.
近年来，随着系统免疫靶向治疗的出现，癌症治疗的治疗选择有了显著的增加。基于免疫检查点阻断或工程化细胞毒性 T 淋巴细胞的新型免疫治疗方法已经进入晚期临床开发阶段，取得了令人鼓舞的结果。癌症免疫疗法的成功极大地激发了人们的兴趣，促使人们进一步开发和探索这些策略，并将其与放疗和肿瘤学中的局部消融疗法等其他方法相结合。本文的目的是讨论当前的免疫治疗方法，并对其作用机制以及某些更常见和更严重的毒性提供简单而有建设性的解释。
